Abstract

Inflammatory bowel diseases (IBDs) have a major effect on quality of life, and achieving clinical remission from IBD can be a lengthy and difficult journey for patients.1 Many patients with IBD require treatment with immunosuppressants, biologicals, hospitalisations, or surgery.1 As well as this disease burden, patients and society must bear the financial consequences of IBD. More than 15 years ago, Ash Bassi and colleagues first examined the total direct cost of IBD care in the UK and reported that the main costs resulted from hospitalisations and surgery.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call